^
Association details:
| Biomarker: | SNX2-ABL1 fusion |
|---|---|
| Cancer: | B Acute Lymphoblastic Leukemia |
| Drug: | imatinib (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, PDGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Identification of FOXP1 and SNX2 as novel ABL1 fusion partners in acute lymphoblastic leukaemia
Excerpt:
"SNX2-ABL1 male B-ALL with t(5;9 (q23;q34)….The presence of the SNX2-ABL1 fusion was confirmed initially by RT-PCR….He responded well to initial chemotherapy but relapsed early. He then received hyper-C VAD and again responded. He relapsed again at the end of 2004 and was started on imatinib, it was transient and despite other supportive measures including hydroxyurea he died in Spring 2005. "
DOI:
10.1111/j.1365-2141.2010.08457
